Hence, the present study is focused on evaluating anticancer potentials of fractions against breast cancer cell line (MDA-MB 231) and human embryonic kidney normal cell line (HEK 293) through Bcl-2 and P53. The gene discussed is TP53; the disease is breast cancer.